The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
What do the preliminary results of the MANIFEST trial say about CPI-0610 in treating MF?
Featured:
Alessandro M. VannucchiVideo series
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Alessandro Vannucchi, University of Florence, IT, about what preliminary results of the MANIFEST trial say about CPI-0610 in treating myelofibrosis?
Vannucchi discusses results from the MANIFEST trial evaluating a BET inhibitor CPI-0610, as a monotherapy or in combination with ruxolitinib, in patients that are transfusion-dependent or independent.
More from this series:
